NxStage narrows loss in Q2 with record revenue

Dialysis devicemaker NxStage ($NXTM) trimmed its losses in the second quarter, reporting all-time high revenues of $59 million, a 10% jump over the previous year.

The company took a $5.1 million loss on the quarter--including a $1 million one-time amortized debt write-off--down from last year's $5.6 million loss, the company reported.

NxStage credits the revenue growth to the expanding adoption of its System One hemodialysis tech, which brought in $40.1 million on the quarter after grossing $35.6 million in the same period last year. At-home sales of the device saw a 14% hike in Q2, pulling in a company-record $30.7 million. Critical care jumped 9% to $9.4 million.

CEO Jeffrey Burbank said NxStage is on track with its growth strategy, getting its products into more and more clinics and households. "Home and more-frequent hemodialysis with the System One is great therapy that has been consistently reported to give patients access to a much richer and longer life," Burbank said in a statement. "We continue to show that our therapy can benefit patients, providers and payers."

Looking forward to Q3, NxStage expects further growth, predicting gross revenue of about $61 million, in part thanks to EU approval of a new feature for System One that automates bolus administration.

- read NxStage's release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.